Here's How You Should Play JNJ Stock After Q1 Earnings Beat

Earlier this week, J&J (JNJ) began the first-quarter earnings season for the drug and biotech sector with better-than-expected results.J&J’s first-quarter adjusted earnings were $2.77 per share, which rose 2.2$21.89 billion rose 2.4% from the year-ago quarter. Innovative Medicines segment sales rose 2.3% year over year to $13.87 billion. MedTech segment sales came in at$8.02 billion, up 2.5% from the year-ago period.The company raised its sales expectations for 2025 by ...